Monopar Therapeutics
MNPR----
Monopar Therapeutics (MNPR)
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Monopar Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$116.856.35%
Forecast & RatingStrong buy
13analysts
- Strong buy69.23%
- Buy30.77%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 1 day ago, 06:27 AM
HC Wainwright Has Positive Outlook of MNPR FY2027 Earnings
- Tip Ranks · 2 days ago, 10:15 AM
Maldonado Reiterates Buy on Monopar as ALXN1840 NDA Progress and Robust Clinical Data Drive Price Target Increase from $105 to $125
- PUBT · Jul 22 at 07:01 AM
Monopar starts rolling FDA NDA submission for ALXN1840 in Wilson disease
- rttnews · Jul 21 at 02:45 AM
Biotech Stocks At 52-Week Highs - XNCR, COAG, MNPR, SOPH, ACRS
- PUBT · Jul 20 at 07:02 AM
Monopar adds ex-KalVista CCO Nicole Sweeny to board
- rttnews · Jul 10 at 07:21 AM
Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT
